(c) Details will be collected and placed on the Table of the House.

(d) There has been no production of Doxycyline and Frusemide by IDPL during the last four years. The production of chloroquin is given below:—

	Production			
	1984-85	1985-86	1986-87	1987-88
Chloroquin T	0.25	1.01	0.10	7.36

(e) Yes, Sir.

(f) Details of licences such as names of companies and capacity issued from time to time are published regularly by India Investment Centre in their monthly Newsletter copies of which are available in parliament Library. Details of production to the extent available are given in the enclosed Statement [*See* Appendix CXLVIII, Annexure No. 126] All these drugs are licensed for production from basic stage.

Sale of Vitamin drugs by IDPL

2940. SHRI ALADI ARUNA ALIAS V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to refer to the answer to Unstarred Question 1232 given in the Rajya Sabha on the 21st November, 1988 and state:

(a) whether it is a fact that IDPL has been licensed to produce Vitamin *B1' B2'* Tetracycline *Hcl* and *Hydroxy*-lamine;

(b) if so, what is the licensed capacity of each and what was the production of each during the last three years, year-wise;

(c) whether it is a fact that Vitamin B_1 and B_2 have been price decontrolled;

(d) if so, what is the present price being charged by IDPL for these drugs;

(e) whether it is a fact that the cost price of each drug is less than one third than the selling price; and

(f) if so, what is the cost price of each of these imported drugs and how much unintended benefit has been made on each?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) and (b) To the extent information is available IDPL is licensed to produce Vitamin B_1 Vitamin B_2 and Tetracycline Hcl. Details of capacity and production are given below:—

Item	Capacity (Tons.)	Production		
		1985-86	1986-87	1987-88
Vitamin B_1	120	58.41	49.85	64.35
Vitamin B_2	24 (Includes capacity for Riboflavin 5 Phosphate Sodium)	24.04	8.69	21 52

(c) Vitamin B1 and B2 as bulk drugs have been exempted from price Control but come under price control under category II when used in combination of formulations

(d) The information to the extent available is given under:—

	Price under DPCO, 1987 (Rs./Kg.)
Vitamin -B1Hcl (Oral Gr.)	1132.00
Vitamin—B1 Hcl (Amp. Gr.)	1176.00
Vitamin—B1 Hcl (Mono)	1228.00
Vitamin—B2	2384.00

(e) and (f) Cost of production details of de-controlled category of drugs are not being monitored by this Department.

Installed capacity of HAL for Vitamin C

2941. SHRI ALADI ARUNA ALIAS V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to state:

(a) what was the investment made by HAL on their Vitamin 'C' plant at original cost;

(b) what is the licensed capacity and installed capacity of Vitamin C of HAL;

(c) what was the production of Vitamin C during the last three year, year-wise;

(d) what capacity of this plant is being utilised at present and what is the capacity that has been set up;

(e) what additional capital expenditure was incurred for setting up this capacity and what was the production during the last three years, year-wise; and

(f) what part of the above production is from basic stages?

THE MINISTER OF INDUSTRY (SHRI J. VENGAL RAO): (a) to (f) The requisite information is being collected and will be laid on the Table of the House.

Overcharging on Phosphomin, Fefol, Fesofar, Vitahext, Santivin and Neurophosphate

2942. SHRI ALADI ARUNA ALIAS V. ARUNACHALAM: Will the Minister of INDUSTRY be pleased to state:

(a) whether it is a fact that prices of Phosphomin, Fefol, Fesofar, Vitahext, Santivin and Neurophosphate are being overcharged inspite of promulgation of DPCO, 1987 more than one year back;

(b) when and what were the prices of these medicines last fixed along with the prices which are being charged for each;

(c) what is the extent of overcharging in each case;

(d) what are the details of the set up of monitoring of prices of his Ministry and what are the names and designations of the officers who are keeping watch on overcharging;

(e) whether it is a fact that manufacturers do not come forward for seeking price approval and continue overcharging; and

(f) what steps have been taken and by when the overcharged amount would be recovered?